Publications by authors named "M R Alborghetti"
Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson's disease (PD). Here we focused on mGlu3, a receptor subtype involved in synaptic regulation and neuroinflammation. mGlu3 mice showed an enhanced nigro-striatal damage and microglial activation in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
View Article and Find Full Text PDFArticle Synopsis
- Trypanosoma cruzi is the protozoan responsible for Chagas Disease, which lacks effective diagnostic and treatment options, prompting a study of its metabolism and adaptation to different environments.
- Recent research shows T. cruzi can utilize various carbon sources, including threonine, during growth and starvation, leading to the discovery of a pathway for threonine degradation.
- The study identified a compound (TCMDC-143160) that inhibits a key enzyme (TcTDH) involved in threonine catabolism, providing insights into potential therapeutic targets for Chagas Disease.
Background: The study demonstrates that pharmacological blockade of type 3 metabotropic glutamate (mGlu3) receptors at the time of tumor induction significantly reduces the incidence of brain gliomas in rats. The overall survival of patients with high-grade brain gliomas is 14-20 months after current multimodal therapy, including surgery, radiotherapy, and adjuvant chemotherapy.
Objective: To demonstrate in this experimental model that pharmacological blockade of group II metabotropic glutamate receptors reduces the incidence of brain tumors induced by prenatal exposure to N- ethyl-N-nitrosourea (ENU) in rats.
Article Synopsis
- Autonomic failure significantly affects the quality of life for individuals with advanced Parkinson's disease (PD), prompting the need to evaluate the impact of Levodopa/carbidopa intestinal gel (LCIG) on autonomic dysfunction.
- A systematic review identified 16 studies involving 1361 PD patients, assessing the effects of LCIG on gastrointestinal, urinary, and cardiovascular symptoms over time, with most studies reporting improvements or stability.
- While many patients benefited from LCIG, some experienced worsening autonomic symptoms and there were reports of mild adverse events related to the treatment, highlighting the need for further targeted research in this area.
Article Synopsis
- * Researchers conducted a computational analysis of the mGlu3 and mGlu5 receptor expression in different grades of gliomas to identify potential treatment targets.
- * The findings revealed a specific type of high-grade glioma, termed neurotransmitter-GBM (NT-GBM), which has unique molecular characteristics and could lead to targeted therapies for this variant.